Michele Aieta

Learn More
Purpose: This study aimed to detect the M30 neoepitope on circulating tumor cells (CTC) as a tool for quantifying apoptotic CTC throughout disease course and treatment. Experimental Design: An automated sample preparation and analysis platform for computing CTC (CellSearch) was integrated with a monoclonal antibody (M30) targeting a neoepitope disclosed by(More)
Off-label use is the practice of prescribing a drug outside the terms of its official labeling. Worldwide, about 20% of the commonly prescribed medications are off-label, and the percentage increases in specific patient populations, such as children, pregnant women, and cancer patients. Off-label use is particularly widespread in oncology for many reasons,(More)
Pancreatic adenocarcinoma displays a variety of molecular changes that evolve exponentially with time and lead cancer cells not only to survive, but also to invade the surrounding tissues and metastasise to distant sites. These changes include: genetic alterations in oncogenes and cancer suppressor genes; changes in the cell cycle and pathways leading to(More)
BACKGROUND Recently, we developed an apoptotic assay for expanding the monitoring capabilities of the circulating tumour cells (CTC) test during therapy. An automated platform for computing CTCs was integrated with a mAb (M30) targeting a neoepitope disclosed by caspase cleavage at cytokeratin 18 in early apoptosis; we showed that live CTCs were associated(More)
BACKGROUND Bone is an uncommon site of metastasis in patients with advanced hepatocellular carcinoma (HCC). Therefore, there are few studies concerning the natural history of bone metastasis in patients with HCC. PATIENTS AND METHODS Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 211 deceased HCC(More)
Background: A systemic immune-inflammation index (SII) based on neutrophil (N), lymphocyte (L), and platelet (P) counts has shown a prognostic impact in several solid tumors. The aim of this study is to evaluate the prognostic role of SII in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone post docetaxel. Patients(More)
BACKGROUND In this retrospective analysis, we explored the prognostic and predictive value of the systemic immune-inflammation index (SII), based on lymphocyte, neutrophil, and platelet counts, at baseline and changes at week 6 during first-line sunitinib in patients with metastatic renal cell cancer (RCC). RESULTS Patients were stratified into high SII(More)
Penile carcinoma is a rare malignancy with incidence rates which vary in the range of 1–10 cases per 100,000 men according to ethnicity, cultural background, geographic area and social habits [1]. Keratinizing squa-mous cell carcinomas, similar to carcinomas of nongenital skin, and verrucous carcinoma are the most common histologic variants, while basaloid(More)
New oncology drugs in the European Union (EU) are assessed under a centralized procedure by the European Medicines Agency (EMA); however, even if a European marketing authorization (MA) has been granted, this does not imply that the product will be available to patients everywhere in the EU [1]. In Italy, new provisions on health care have been introduced(More)
  • 1